Related Experiment Video
Updated: Jul 16, 2026
06:32
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
IFI16 in human prostate cancer.
Fatouma Alimirah1, Jianming Chen, Francesca J Davis
1Department of Radiation Oncology, Loyola University Chicago, Illinois, USA.
Molecular Cancer Research : MCR
|March 7, 2007
Summary
IFI16 gene silencing in prostate cancer cells contributes to tumor development. Histone deacetylase inhibitors can reactivate IFI16, reducing androgen receptor levels and promoting apoptosis, offering a potential therapeutic strategy.
Area of Science:
- Molecular Biology
- Cancer Research
- Cellular Senescence
Background:
- IFI16 protein expression is linked to growth arrest in normal prostate cells.
- IFI16 is downregulated in human prostate cancer cell lines.
- Understanding IFI16 regulation is crucial for prostate cancer research.
Purpose of the Study:
- To investigate the transcriptional regulation of the IFI16 gene in prostate cancer cells.
- To explore the role of histone deacetylase inhibitors in IFI16 expression.
- To determine the functional consequences of IFI16 re-expression in prostate cancer.
Main Methods:
- Treatment of prostate cancer cell lines (DU-145, LNCaP) with histone deacetylase inhibitors (trichostatin A, CGK1026).
- Analysis of IFI16 gene and protein expression.
- Investigation of the role of c-Jun/activator protein-1 transcription factor.
- Assessment of androgen receptor and apoptosis markers.
- Knockdown of IFI16 expression.
Main Results:
- Histone deacetylase inhibitors induced IFI16 gene transcription in prostate cancer cells.
- TSA treatment upregulated Janus-activated kinase 1 and modulated IFN-activatable genes, but JAK1/IFN did not affect IFI16.
- IFI16 transcriptional activation by TSA was dependent on c-Jun/activator protein-1.
- Increased IFI16 expression correlated with decreased androgen receptor and increased apoptosis.
- IFI16 knockdown reversed these effects.
Conclusions:
- Histone deacetylase-dependent transcriptional silencing of IFI16 contributes to prostate cancer development.
- Re-expression of IFI16 via histone deacetylase inhibitors shows potential in targeting prostate cancer by affecting androgen receptor signaling and apoptosis.
